The percentage of ROR-med/high patients within the Ki67 0-10% group was 42.7% (within tumor size ≤2 cm) and 33.9% (within tumor size > 2 cm) (Table 1 and Supplementary Table 4). This evidence concerns the gene MKI67 and neoplasm.